During the disease process, up to 40% of patients with NSCLC develop brain metastases, and patients with EGFR mutations have a greater risk of brain metastases (OR = 3.83, 95% CI = 1.72–8.55; p = 0.001) [36, 37]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.